Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity.

Here, we review the performance of chromatographic hydrophobicity measurements in a data set of 100,000 GlaxoSmithKline compounds, demonstrating the advantages of the method over octanol-water partitioning and highlighting new insights for drug discovery. The value of chromatographic measurements, versus other hydrophobicity estimates, was supported by improved relationships with solubility, permeation, cytochrome P450s, intrinsic clearance, hERG binding and promiscuity. We also observed marked differentiation of the relative influence of intrinsic and effective hydrophobicity. The summing of hydrophobicity values plus aromatic ring count [logD(pH7.4) (or logP)+#Ar], indicated a wide relevance for simplistic 'property forecast indices' in developability assays, clearly enhanced by chromatographic values; therefore establishing new foundations for enriching property-based drug design.

[1]  M. Hann.  Molecular obesity, potency and other addictions in drug discovery , 2011 .

[2]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[3]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[4]  Hongyu Zhao.  Lead optimization in the nondrug-like space. , 2011, Drug discovery today.

[5]  P. Woollard,et al.  2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. , 2005, Journal of medicinal chemistry.

[6]  I. E. Smith,et al.  Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. , 2006, Journal of medicinal chemistry.

[7]  Kiyohiko Sugano,et al.  Introduction to computational oral absorption simulation. , 2009, Expert opinion on drug metabolism & toxicology.

[8]  Paige L. Williams,et al.  Quantitative Structure‐Activity Relationships (QSARs) , 2006 .

[9]  T. Ritchie,et al.  The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? , 2009, Drug discovery today.

[10]  David J. Diller,et al.  In Silico hERG Modeling: Challenges and Progress , 2009 .

[11]  L. Di,et al.  Physicochemical profiling: overview of the screens. , 2004, Drug discovery today. Technologies.

[12]  J. Hughes,et al.  Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.

[13]  Aditya Mittal,et al.  Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. , 2004, Journal of pharmaceutical sciences.

[14]  Paul D. Leeson,et al.  Reducing the Risk of Drug Attrition Associated with Physicochemical Properties , 2010 .

[15]  Stefan Senger,et al.  Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs. , 2010, Bioorganic & medicinal chemistry letters.

[16]  M. Waring.  Lipophilicity in drug discovery , 2010, Expert Opinion on Drug Discovery.

[17]  R. Austin,et al.  A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.

[18]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[19]  Miguel A R B Castanho,et al.  Drug-lipid interaction evaluation: why a 19th century solution? , 2010, Trends in pharmacological sciences.

[20]  G. Trainor,et al.  The importance of plasma protein binding in drug discovery , 2007, Expert opinion on drug discovery.

[21]  John P. Overington,et al.  Probing the links between in vitro potency, ADMET and physicochemical parameters , 2011, Nature Reviews Drug Discovery.

[22]  A. Bast,et al.  Dependence of hydrogen peroxide formation in rat liver microsomes on the molecular structure of cytochrome P-450 substrates: A study with barbiturates and β-adrenoceptor antagonists , 1989, European Journal of Drug Metabolism and Pharmacokinetics.

[23]  M. Abraham,et al.  Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. , 2003, Journal of pharmaceutical sciences.

[24]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[25]  J. Peters,et al.  Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.

[26]  Jens Sadowski,et al.  Properties Guiding Drug‐ and Lead‐Likeness , 2007 .

[27]  Maurice Dickins,et al.  Compound lipophilicity for substrate binding to human P450s in drug metabolism. , 2004, Drug discovery today.

[28]  Edward H. Kerns,et al.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.

[29]  Stephen D Pickett,et al.  The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. , 2011, Drug discovery today.

[30]  Paul D. Leeson,et al.  Impact of ion class and time on oral drug molecular properties , 2011 .

[31]  C. Bevan,et al.  Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC:  A High-Throughput Alternative to log P/log D. , 1997, Analytical chemistry.

[32]  M. Tute.  Lipophilicity: A History , 2008 .

[33]  H. Waterbeemd.  Improving compound quality through in vitro and in silico physicochemical profiling. , 2009 .

[34]  K. Wanner,et al.  Methods and Principles in Medicinal Chemistry , 2007 .

[35]  D. Lewis,et al.  Quantitative structure-activity relationships (QSARs) in inhibitors of various cytochromes P450: The importance of compound lipophilicity , 2007, Journal of enzyme inhibition and medicinal chemistry.

[36]  Li Di,et al.  Coexistence of passive and carrier-mediated processes in drug transport , 2010, Nature Reviews Drug Discovery.

[37]  K. Valko,et al.  Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. , 2004, Journal of chromatography. A.

[39]  A. Hill,et al.  Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. , 2010, Drug discovery today.

[40]  M. Gleeson.  Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[41]  M. Waring,et al.  A quantitative assessment of hERG liability as a function of lipophilicity. , 2007, Bioorganic & medicinal chemistry letters.

[42]  M. L. Howard,et al.  Plasma protein binding in drug discovery and development. , 2010, Combinatorial chemistry & high throughput screening.

[43]  C. Hansch,et al.  A NEW SUBSTITUENT CONSTANT, PI, DERIVED FROM PARTITION COEFFICIENTS , 1964 .

[44]  P. Artursson.  Cell cultures as models for drug absorption across the intestinal mucosa. , 1991, Critical reviews in therapeutic drug carrier systems.

[45]  A. Holmén,et al.  High throughput screening of physicochemical properties and in vitro ADME profiling in drug discovery. , 2009, Combinatorial chemistry & high throughput screening.

[46]  Dino Montanari,et al.  Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates , 2010, Expert opinion on drug discovery.

[47]  Ian A. Watson,et al.  Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.

[48]  Richard D. Cramer,et al.  BC(DEF) parameters. 1. The intrinsic dimensionality of intermolecular interactions in the liquid state , 1980 .

[49]  Maurice Dickins,et al.  Substrate SARs in human P450s. , 2002, Drug discovery today.

[50]  Michael J Allen,et al.  The discovery of GSK221149A: a potent and selective oxytocin antagonist. , 2008, Bioorganic & medicinal chemistry letters.

[51]  M. Waring.  Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. , 2009, Bioorganic & medicinal chemistry letters.

[52]  Hugo Kubjnyi,et al.  Drug Partitioning: Relationships between Forward and Reverse Rate Constants and Partition Coefficient , 1978 .

[53]  C. Hansch,et al.  Selection of a reference partitioning system for drug design work. , 1975, Journal of pharmaceutical sciences.

[54]  M. Edwards,et al.  Using the Golden Triangle to optimize clearance and oral absorption. , 2009, Bioorganic & medicinal chemistry letters.

[55]  A. Leo.  CALCULATING LOG POCT FROM STRUCTURES , 1993 .

[56]  Z. Rankovic,et al.  Medicinal chemistry of hERG optimizations: Highlights and hang-ups. , 2006, Journal of medicinal chemistry.

[57]  C. Vergely,et al.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.